MOTS-c Buying Guide: How to Source Research-Grade MOTS-c for Canadian Laboratories

Sourcing MOTS-c presents specific challenges that don't apply to more established research peptides. The compound is relatively new — identified only in 2015 — which means fewer suppliers have deep synthesis experience with it, more suppliers have inconsistent quality controls, and the market includes a significant number of low-quality vendors selling mislabeled or underdosed products. For Canadian research laboratories, this makes sourcing decisions higher-stakes than for compounds like BPC-157 or TB-500 that have decades of established synthesis history.

This buying guide provides a complete framework for evaluating MOTS-c suppliers — what quality specifications to require, how to verify identity and purity, what documentation should accompany every vial, what pricing signals suggest quality trade-offs, and what red flags indicate suppliers to avoid. The framework applies to any MOTS-c supplier, including us.

For background on what MOTS-c is and how it functions, see What Is MOTS-c? A Complete Guide to the Mitochondrial-Derived Peptide and How Does MOTS-c Work? Understanding the Folate-AICAR-AMPK Pathway. Our MOTS-c research peptide is supplied at ≥99% HPLC purity with mass-spec-verified identity and batch-specific COAs for laboratory research applications only.

The Six Sourcing Criteria for Research-Grade MOTS-c

Research-grade MOTS-c must meet six specific criteria: ≥99% HPLC-verified purity, mass spectrometry identity confirmation matching the 2,174 Da theoretical molecular weight, batch-specific certificates of analysis, cold-chain shipping integrity, established supplier synthesis experience, and appropriate regulatory compliance framing. Each criterion addresses a specific risk factor in MOTS-c sourcing, and skipping any one of them compromises research reproducibility.

The framework applies to any peptide supplier, but MOTS-c specifically requires additional attention because the compound's novelty means quality variance is higher than for established research peptides. A supplier who reliably delivers BPC-157 may not have the same synthesis experience with MOTS-c. Each of the six criteria below addresses a specific risk that MOTS-c sourcing presents.

Criterion 1: HPLC Purity at ≥99%

Research-grade MOTS-c should meet a minimum ≥99% HPLC purity standard, with batch-specific chromatograms available for verification — anything below 99% introduces synthesis impurities that can produce biological effects of their own, confound assays, and compromise reproducibility. Some vendors report 95-98% purity grades, which are inadequate for careful research applications.

Why 99% matters specifically for MOTS-c

MOTS-c synthesis produces potential impurities that share structural similarity to the target peptide — deletion sequences (peptides missing one or two amino acids), oxidation products, and synthesis intermediates. These impurities are structurally close enough to MOTS-c that they may bind related molecular targets or produce their own biological effects. At 97% purity, 3% of the material is impurity. In a 10mg vial, that's 300 micrograms of contaminating compounds — enough to produce measurable off-target effects in sensitive assays.

What HPLC documentation should show

The certificate of analysis should include the actual HPLC chromatogram, not just a stated purity percentage. The chromatogram should show a single dominant peak corresponding to MOTS-c, with any minor peaks clearly identified and quantified. Suppliers who provide only a purity number without the chromatogram are asking you to take their measurement on faith. Peer-reviewed research on peptide synthesis quality control standards is available through PubMed peptide purity research.

Criterion 2: Mass Spectrometry Identity Confirmation

Mass spectrometry identity confirmation is critical for MOTS-c specifically because HPLC purity doesn't verify compound identity — a peptide can be 99% pure and still be the wrong compound. MOTS-c has a specific theoretical molecular weight of approximately 2,174 Da that MS analysis can confirm; suppliers who cannot provide MS-verified identity documentation introduce unnecessary compound identity risk.

The specific MOTS-c mass signature

MOTS-c is a 16-amino-acid peptide with the sequence MRWQEMGYIFYPRKLR. Its theoretical molecular weight (calculated from amino acid residues) is approximately 2,174 Da. Mass spectrometry analysis should confirm this value within standard tolerances. Batch-specific MS spectra should show a clear peak at the expected molecular weight, without significant secondary peaks that would indicate contaminating peptides or synthesis errors.

Why this matters for a novel peptide

For established peptides like BPC-157, TB-500, or Retatrutide, synthesis protocols are well-optimized and identity errors are rare. MOTS-c is different. As a relatively new compound (identified 2015, synthesis protocols still maturing), identity verification is more important. Some suppliers new to MOTS-c may produce peptides with sequence errors, wrong terminal modifications, or incorrect residue substitutions — all of which pass HPLC purity tests but fail MS identity verification.

Criterion 3: Batch-Specific Certificates of Analysis

Certificates of analysis for MOTS-c must be batch-specific — referencing the specific lot number printed on your vial, the manufacturing date, the specific HPLC chromatogram, and the specific MS identity spectrum. Generic COAs that reference "typical" purity or omit batch numbers provide effectively no quality assurance and are red flags for supplier reliability.

What a legitimate COA includes

A research-grade COA for MOTS-c should include: the specific lot or batch number that matches your vial label; the manufacturing and analysis dates; the HPLC chromatogram showing the purity determination; the mass spectrometry spectrum confirming identity; the reported purity percentage with reference to the analytical method; the peptide sequence; and any additional testing performed on the batch.

Red flags in COA documentation

Several documentation patterns indicate suppliers to avoid: COAs without specific batch numbers, COAs that appear to be reused across multiple orders, COAs that don't reference the specific analytical date, purity percentages without accompanying chromatograms, or documentation that appears templated rather than batch-generated. A supplier who can't produce a batch-specific COA on request cannot support research designs requiring analytical traceability. For a broader framework on evaluating supplier documentation, see Emerald Peptides vs. Other Brands: 7 Standards That Separate Quality Research Peptide Suppliers.

Criterion 4: Cold-Chain Shipping and Storage Integrity

Lyophilized MOTS-c requires cold-chain integrity during shipping and appropriate storage conditions after arrival — 2-8°C protected from light for short-term storage and -20°C for long-term storage — because thermal cycling during transit and improper storage after receipt both compromise peptide stability. Cross-border shipments carry particular risk due to customs delays and temperature variations.

Why domestic Canadian shipping matters for MOTS-c

MOTS-c's 16-amino-acid structure is relatively short and stable in lyophilized form, but the compound isn't immune to degradation from thermal cycling. International shipments to Canada from US or offshore suppliers can accumulate temperature variations, customs holds of unpredictable duration, and unmonitored transit times. Domestic Canadian shipping eliminates these variables. Peptides synthesized and shipped within Canada arrive at your laboratory having experienced fewer stability-affecting variables than internationally sourced equivalents.

Storage after arrival

Once MOTS-c arrives at your laboratory, storage matters as much as sourcing. Lyophilized MOTS-c should be stored at 2-8°C protected from light for short-term use (weeks). Long-term storage should be at -20°C or lower to maintain peptide stability over months. After reconstitution, working solutions should be aliquoted to minimize freeze-thaw cycles. For detailed storage protocols, see How to Store Research Peptides for Stability and Lab Use.

Criterion 5: Established Supplier Synthesis Experience

Because MOTS-c is a relatively novel research peptide (identified only in 2015), supplier experience with the specific compound matters more than for established peptides — established suppliers with track records in analytically challenging peptides like Semax, Selank, or AOD-9604 are preferable to suppliers new to MOTS-c. Supplier operational continuity and analytical infrastructure become more important, not less, for newer compounds.

What established supplier experience looks like

A supplier with meaningful MOTS-c synthesis experience will have: multiple years of active operations (not a supplier that appeared in the past 12 months); established synthesis protocols documented internally; in-house analytical capability rather than exclusive third-party outsourcing; a track record with structurally similar peptides; and consistent batch-to-batch quality data. These characteristics reflect the operational maturity needed to reliably produce MOTS-c at research-grade specifications.

Why supplier turnover matters for MOTS-c specifically

The research peptide market has high turnover, with many suppliers operating for less than 24 months before discontinuing. For MOTS-c, this turnover carries specific risks. If your supplier discontinues operations mid-way through a longitudinal research project, sourcing continuity fails — and finding a new supplier with matching quality specifications for a compound as novel as MOTS-c is harder than for BPC-157 or similar established compounds. Established suppliers with multi-year track records reduce this continuity risk substantially.

Criterion 6: Compliance Framing and Regulatory Positioning

MOTS-c is investigational and not FDA approved for any human therapeutic use as of mid-2026 — legitimate suppliers frame MOTS-c strictly as a research compound for laboratory use only, provide compliance documentation, and do not market MOTS-c for human consumption or therapeutic applications. Suppliers who market MOTS-c for weight loss, athletic performance, or anti-aging use to end consumers are operating outside legitimate research supply frameworks.

Legitimate research supply framing

A legitimate MOTS-c supplier for research applications will consistently frame the compound as "for research use only" or "for laboratory research applications." Product pages should not include dosing recommendations for humans, therapeutic claims, or marketing directed at end consumers seeking self-administration. The compliance framing matters both for regulatory reasons and as a signal of supplier legitimacy — suppliers who market outside research frameworks are also often less rigorous about quality controls.

The current regulatory status

MOTS-c is not FDA approved for any human therapeutic use. The current Phase 2a trial (NCT07505745) in prediabetes patients represents the first substantial human clinical investigation and does not constitute regulatory approval. Health Canada has not approved MOTS-c for any human or veterinary use. Research-grade MOTS-c is legal to source for laboratory research applications in Canada, but sale for human consumption falls outside legitimate research supply. Clinical trial documentation is available through ClinicalTrials.gov NCT07505745.

Pricing Considerations and Value Assessment

Research-grade MOTS-c pricing in 2026 reflects genuine synthesis and quality control costs — reputable suppliers charge approximately $16-22 per 5mg vial and $32-45 per 10mg vial, with prices significantly below this range typically signaling quality trade-offs. The lowest-price supplier is rarely the best sourcing choice for research applications where reproducibility matters.

What legitimate MOTS-c pricing reflects

MOTS-c synthesis at ≥99% HPLC purity with MS-verified identity requires substantial analytical infrastructure, skilled synthesis chemistry, and batch-by-batch quality control. Suppliers who maintain these standards have real operating costs that get reflected in pricing. When a supplier offers MOTS-c at 40-50% below reputable market pricing, that discount typically comes from cutting corners — either lower actual purity, generic COAs rather than batch-specific documentation, offshore synthesis with limited quality controls, or all three.

The false economy of low-price sourcing

For research applications, the cost of unreliable compounds is far higher than the price differential of quality sourcing. A single failed experiment traceable to compound quality issues costs more in wasted time, materials, and researcher attention than a full year's premium sourcing for MOTS-c. Research designs that need to publish results, pass peer review, or contribute to a body of literature cannot tolerate compound quality variance — which makes premium sourcing the actual cost-effective choice.

Canadian pricing considerations

Canadian researchers sourcing MOTS-c domestically avoid several cost factors that inflate international sourcing — cross-border shipping fees, customs handling, currency conversion, and potential importation delays. Direct Canadian sourcing at established quality specifications is typically comparable to or better than international sourcing on total cost, once these factors are included.

Red Flags: Suppliers to Avoid

Several patterns reliably identify MOTS-c suppliers to avoid — vendors selling below reputable market pricing, generic COAs without batch numbers, missing HPLC chromatograms, missing MS identity data, suppliers new to the market with no operational history, and vendors marketing MOTS-c for human consumption or therapeutic use. Any one of these patterns should prompt caution; multiple patterns together indicate a supplier to avoid entirely.

Documentation red flags

Watch for: COAs without specific batch numbers or analytical dates; purity claims without accompanying HPLC chromatograms; missing mass spectrometry data; documentation that appears templated rather than batch-generated; certificates that don't match the compound description; and inconsistencies between website product descriptions and delivered documentation.

Marketing red flags

Watch for: MOTS-c marketed for weight loss, athletic performance, or anti-aging use directly to consumers; product pages including human dosing recommendations; therapeutic claims about human health outcomes; testimonials from consumers rather than researchers; and pricing significantly below reputable market rates. These patterns typically correlate with less rigorous quality controls.

Operational red flags

Watch for: suppliers with no operational history, no analytical infrastructure references, offshore-only synthesis with unclear origins, changing brand names or business identities, poor customer service responsiveness to specific quality questions, and inability to answer detailed questions about batch synthesis or testing methodology.

Why Canadian Domestic Sourcing Matters for MOTS-c

Canadian domestic sourcing eliminates several risk factors specific to international MOTS-c procurement — customs delays that expose peptides to thermal cycling, complex return logistics if quality issues arise, currency conversion adding to costs, and regulatory ambiguity around cross-border research peptide shipments. For Canadian research laboratories, domestic sourcing is typically the higher-quality choice on multiple dimensions simultaneously.

The specific advantages compound: peptides synthesized in Canada under Canadian analytical oversight avoid the transparency gaps of offshore manufacturing; domestic shipping eliminates customs-related transit variables; Canadian suppliers can respond to batch-specific quality questions within hours rather than weeks; and Canadian regulatory frameworks provide clear compliance context for research applications. Our MOTS-c product page details our specific sourcing and quality standards for Canadian research applications, and our Longevity & Mitochondrial Collection covers MOTS-c alongside related mitochondrial and aging research compounds.

Frequently Asked Questions

What purity standard should MOTS-c meet for research applications?

Research-grade MOTS-c should meet a minimum ≥99% HPLC purity standard verified with batch-specific chromatograms. Lower purity grades (95-98%) may pass casual inspection but introduce synthesis impurities that can produce biological effects of their own, confound assays, and compromise research reproducibility. The 99% standard should be documented on batch-specific certificates of analysis showing the actual HPLC chromatogram, not just a stated purity number.

How do I verify MOTS-c identity?

MOTS-c identity is verified through mass spectrometry, which measures the compound's molecular weight and compares it against the theoretical value of approximately 2,174 Da for the 16-amino-acid peptide (sequence MRWQEMGYIFYPRKLR). Batch-specific MS spectra should be included in certificates of analysis. Suppliers who cannot provide MS-verified identity documentation introduce unnecessary risk that the compound in the vial isn't what the label claims.

How much should MOTS-c cost from reputable suppliers?

Research-grade MOTS-c pricing in 2026 typically ranges from approximately $16-22 per 5mg vial and $32-45 per 10mg vial from reputable suppliers meeting ≥99% HPLC purity standards with batch-specific documentation. Prices significantly below this range typically signal quality trade-offs — lower actual purity, generic COAs, offshore synthesis with limited quality controls, or combinations of these issues. Canadian domestic sourcing at established quality specifications is typically comparable to international sourcing on total cost when shipping, customs, and currency factors are included.

What documentation should accompany MOTS-c shipments?

Every MOTS-c vial should ship with batch-specific documentation including: certificate of analysis with matching lot number; HPLC chromatogram showing ≥99% purity; mass spectrometry spectrum confirming identity; manufacturing and analysis dates; and peptide sequence documentation. Generic COAs without batch numbers, missing HPLC chromatograms, or missing MS data are red flags indicating suppliers to avoid.

How should MOTS-c be stored after arrival?

Lyophilized MOTS-c should be stored at 2-8°C protected from light for short-term use (weeks). Long-term storage requires -20°C or lower to maintain peptide stability over months. After reconstitution in appropriate solvent (typically bacteriostatic water or sterile saline), working solutions should be aliquoted to minimize freeze-thaw cycles. Reconstituted MOTS-c should be used within the timeframe specified by the supplier, typically 30 days at 2-8°C or longer at -20°C.

Is MOTS-c legal to source for research in Canada?

Research-grade MOTS-c is legal to source for laboratory research applications in Canada. However, MOTS-c is not approved by Health Canada or any other regulatory agency for human or veterinary use. Sale for human consumption falls outside legitimate research supply frameworks. Research peptide suppliers do not sell MOTS-c for therapeutic purposes, and all vials are supplied strictly for laboratory research use only.

Where should Canadian researchers buy MOTS-c?

Canadian research labs sourcing MOTS-c should prioritize suppliers meeting six criteria: ≥99% HPLC-verified purity, mass spectrometry identity confirmation, batch-specific certificates of analysis, cold-chain shipping integrity with Canadian domestic supply, established supplier synthesis experience with track record in analytically challenging peptides, and appropriate regulatory compliance framing. Our MOTS-c research peptide meets all six criteria with fast domestic Canadian shipping.

⚠️ For research use only. Not intended for human or veterinary use. Not a drug, food, or supplement.